Yair Sapir

This inventor holds 13 USPTO granted patents and 16 published patent applications, plus 5 CIPO patents and 6 EPO patents. Top assignees: Biond Biologics Ltd., Famewave Ltd., Ccam Biotherapeutics Ltd.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yair Sapir. Retrieved from https://idiyas.com/inventor/yair-sapir

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 16)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 11)

EPO Patents = 6 (Patent Applications = 20)

Average Co-Inventor Count = 7.7

ph-index = 2

Forward Citations = 14(Granted Patents)

Location History:

Burgata, IL (2017 - 2024)
Manof, IL (2018 - 2024)

Company Filing History:

Ccam Biotherapeutics Ltd.

Years Active: 2017-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12589163 - SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY (2026-03-31),

2. 12544451 - INTRACELLULAR DELIVERY COMPOSITIONS (2026-02-10),

3. 12503510 - SMALL SHEDDING BLOCKING AGENTS (2025-12-23),

4. 12391755 - Methods of use for anti-ILT2 antibodies (2025-08-19),

5. 12139534 - Methods and compositions for decreasing soluble immune receptor CD28 (2024-11-12),

6. 12071479 - Antibodies against ILT2 and use thereof (2024-08-27),

7. 11891453 - Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM) (2024-02-06),

8. 11866509 - Humanized antibodies against CEACAM1 (2024-01-09),

9. 11427647 - Polynucleotides encoding humanized antibodies against CEACAM1 (2022-08-30),

10. 11236162 - Antibodies against ILT2 (2022-02-01),

11. 10550196 - Humanized antibodies against CEACAM1 (2020-02-04),

12. 10081679 - Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy (2018-09-25),

13. 9771431 - Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM) (2017-09-26),

Title: Yair Sapir: Innovator in Biopharmaceuticals

Introduction

Yair Sapir is a notable inventor based in Israel, recognized for his contributions to the field of biopharmaceuticals. With a focus on intracellular delivery systems and humanized antibodies, he has made significant strides in medical research and innovation.

Latest Patents

Yair Sapir has developed several innovative patents, although he currently holds no patents registered under his name. His latest work includes the development of intracellular delivery compositions, which feature protein conjugates that utilize polyethylenimine as a carrier. These compositions are designed to interact with intracellular targets, providing a novel approach to drug delivery. Additionally, he has worked on humanized antibodies against CEACAM1, which are capable of binding specifically to human CEACAM1 molecules. These antibodies have potential applications in treating and diagnosing cancer, showcasing his commitment to advancing medical science.

Career Highlights

Throughout his career, Yair Sapir has been associated with prominent companies such as Famewave Ltd. and Tel Hashomer Medical Research Infrastructure and Services Ltd. His work in these organizations has allowed him to contribute to groundbreaking research and development in the biopharmaceutical sector.

Collaborations

Yair has collaborated with several professionals in his field, including Tehila Ben-Moshe and Ilana Mandel. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Yair Sapir's work in biopharmaceuticals highlights his innovative spirit and dedication to improving healthcare through scientific advancements. His contributions to intracellular delivery systems and humanized antibodies are paving the way for future breakthroughs in medicine.

Profile summary based on public USPTO records.